Cartesian Stock Price, News & Analysis

Cartesian Therapeutics (NASDAQ: RNAC) has initiated its Phase 3 AURORA trial for Descartes-08, enrolling the first participant to treat myasthenia gravis (MG). Descartes-08 is an autologous CAR-T cell therapy targeting BCMA, designed for outpatient administration without preconditioning chemotherapy. The Phase 3 trial will evaluate Descartes-08 against placebo in approximately 100 AChR Ab+ MG patients. Previous Phase 2b results showed promising efficacy, with patients experiencing an average 4.8-point reduction in MG-ADL scores at 12 months. Notably, treatment-naive patients showed even better results with a 7.1-point reduction, and 57% maintained minimum symptoms at 12 months. The AURORA trial's primary endpoint will measure the proportion of participants achieving a ≥3-point improvement in MG-ADL score at Month 4 compared to placebo.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. The company's management will participate in a fireside chat, which will be available via live webcast on Cartesian's website. An archived replay will also be accessible for a limited time in the Events section at www.cartesiantherapeutics.com.

Cartesian Therapeutics (NASDAQ: RNAC) reported its Q1 2025 financial results and provided significant pipeline updates. The company's lead candidate Descartes-08 showed promising Phase 2b results in myasthenia gravis (MG), with sustained benefits through 12 months after a single course of therapy. Notably, patients without prior biologic exposure showed an average 7.1-point reduction in MG-ADL, with 57% maintaining minimum symptoms at Month 12.

The company plans to initiate the Phase 3 AURORA trial for Descartes-08 in MG in Q2 2025. Additional milestones expected in H2 2025 include preliminary data from a Phase 2 trial in systemic lupus erythematosus and initiation of a pediatric basket trial. Financially, Cartesian reported $182.1 million in cash and equivalents as of March 31, 2025, expected to fund operations into mid-2027. Q1 2025 net loss was $(17.7) million, or $(0.68) per share.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, has granted inducement awards to five new employees. The awards consist of options to purchase 27,700 shares of common stock at an exercise price of $12.27 per share, matching the closing price on Nasdaq Global Market on May 1, 2025.

The options were issued under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and will vest 25% on May 1, 2026, followed by three equal annual installments until full vesting on May 1, 2029. The options have a ten-year term and were granted under Nasdaq Listing Rule 5635(c)(4).

Cartesian Therapeutics (NASDAQ: RNAC) announced promising 12-month data from its Phase 2b trial of Descartes-08, a CAR-T cell therapy for myasthenia gravis (MG). After a single six-week treatment course, patients showed sustained benefits with an average 4.8-point reduction in MG-ADL at Month 12.

Key highlights:

• Patients without prior biologic therapy exposure showed the strongest response, with a 7.1-point reduction in MG-ADL and 57% maintaining minimum symptom expression at Month 12
• 83% of evaluable participants maintained clinically meaningful response through Month 12
• Safety profile remained favorable with no cytokine release syndrome or neurotoxicity cases
• Treatment was administered in outpatient setting without chemotherapy

The company received FDA's RMAT and Orphan Drug Designations for Descartes-08, and plans to initiate the Phase 3 AURORA trial in Q2 2025.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on autoimmune disease cell therapies, has granted inducement awards to four new employees. The awards consist of options to purchase a total of 31,000 shares of company common stock at an exercise price of $12.49 per share, matching the closing price on Nasdaq Global Market on April 1, 2025.

The options were issued under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and received board approval. The vesting schedule includes 25% vesting on April 1, 2026, followed by three equal annual installments, achieving full vesting by April 1, 2029. These ten-year term options were granted under Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. ET. Investors and interested parties can access the live webcast through the Events section of Cartesian's website at www.cartesiantherapeutics.com. An archived replay will be available for a time after the event.

Cartesian Therapeutics (NASDAQ: RNAC) has reported its full year 2024 financial results and provided key business updates. The company maintains a strong financial position with $214.3 million in cash and equivalents, expected to fund operations into mid-2027.

Key pipeline developments include:

• Phase 3 AURORA trial of Descartes-08 for myasthenia gravis set to begin in 1H25, supported by FDA Special Protocol Assessment agreement
• Positive Phase 2b trial results showing durable responses over 12 months in Descartes-08-treated participants
• Ongoing Phase 2 trial of Descartes-08 for systemic lupus erythematosus with data expected in 2H25
• Planned Phase 2 pediatric basket trial initiation in 2H25

Financial results show R&D expenses decreased to $45.1 million from $71.3 million in 2023, while G&A expenses reduced to $30.1 million from $40.5 million. Net loss for 2024 was $(77.4) million, or $(4.48) per share, compared to $(219.7) million in 2023.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has granted an employment inducement award to a new employee. The award consists of an option to purchase 2,650 shares of company common stock at an exercise price of $17.50 per share, matching the closing price on Nasdaq Global Market on the grant date of March 3, 2025.

The option was issued under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and follows Nasdaq Listing Rule 5635(c)(4). The vesting schedule includes 25% vesting on March 3, 2026, followed by three equal annual installments, achieving full vesting by March 3, 2029. The option carries a ten-year term.